Bacil Pharma (524516)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trailing ROE of 43.68% indicates some profitability on a tiny equity base.
• Piotroski F-Score of 5/9 suggests moderate financial health, not outright distress.
• Zero reported debt (Debt/Equity N/A) limits immediate solvency risk.
• Profit growth of 166.67% shows some positive momentum from a very low base.

Concerns

• Latest quarter shows ₹0 Cr sales and ₹0 Cr net profit — no actual operating business.
• ROCE of -0.97% proves capital is not being deployed productively in operations.
• P/B of 15.39 and P/E of 93.78 are absurdly expensive for a company with zero revenue.
• Current price ₹17.54 is below the stated 52-week low of ₹26.69, indicating severe downtrend and possible illiquidity.

AI Analysis

When I look at Bacil Pharma, I see a micro-cap that fails Graham’s first test: it is a business. Sales are zero, the latest quarter shows ₹0 Cr revenue and ₹0 Cr profit. Yet the market prices it at ₹11 Cr, or 15.39 times book value of ₹1.14 per share. That is not investing; it is hoping. The P/E of 93.78 means the trailing earnings are minuscule — roughly ₹0.12 Cr — and the so-called profit growth of 166.67% is from a near-zero base, meaningless for projecting the future. ROE of 43.68% looks impressive, but with zero sales and negative ROCE of -0.97%, the earnings are not coming from a productive operating business. This is likely financial engineering, other income, or a one-off. There is no moat, no pricing power, no competitive advantage. The stock trades at ₹17.54, far below its 52-week range of ₹26.69–₹61.80, which tells me the market has already started waking up to reality. Promoter holding is not disclosed — a red flag for minority shareholders. I see no margin of safety. Benjamin Graham taught us to buy dollar bills for 50 cents. Here we are asked to pay ₹15 for every ₹1 of book value, for a company that cannot generate a single rupee of sales. This is not a business; it is a stock certificate. The only rational approach is to avoid it entirely and wait for a company with real earnings, real assets, and a price that compensates for risk.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer